Published in J Hepatol on April 08, 2020
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. J Hepatol (2020) 1.38
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol (2020) 1.38
Lack of genetic evidence that fatty liver disease predisposes to COVID-19. J Hepatol (2020) 1.08
Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease. J Hepatol (2021) 0.75
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut (2020) 0.75
Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'. J Hepatol (2020) 0.75
Reply to: 'NAFLD or comorbidities, that is the question'. J Hepatol (2020) 0.75
Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'. J Hepatol (2020) 0.75